What can you tell us about that?

Yes.

So as we are going through the denials, they were citing what protocol they use for the denials.

And so they said they use a certain medical policy for prior authorization.

I had pulled that up and took a look at it.

And they have a certain pathway for oncology medication approvals and rare oncologic disorders.

And so in there, it states that they use the NCCN guidelines to make determinations.

So Dr. Stallman, what policy solutions do you support to prevent these kinds of potentially life-threatening denials in the future?

And so what challenges did you come across with your insurer, health insurer, Blue Cross of Idaho to get that treatment covered?

Yes.

So the mutation was targetable by a medication called lorlatinib.

And this was reviewed by a few different institutions.

Everyone agreed that lorlatinib is the best medication for her.

So then our doctor put in the request, put in the prior authorization.

We thought it would be a pretty clear cut case of Here's a mutation.

So what did it take for Blue Cross of Idaho to finally cover the medicine that she needed to shrink her tumor?